Instructions for use of Ixazomib/Enleri: indications, usage, dosage and precautions

Ixazomib is an oral proteasome inhibitor mainly used to treat multiple myeloma (MM). It inhibits the proteasome in cancer cells through a specific mechanism of action, thereby preventing tumor growth and expansion. Ixazomib is often used in combination with Lenalidomide and Dexamethasone to enhance its efficacy. Since being approved by the US FDA in 2015, ixazomib has become one of the important drugs in the treatment of multiple myeloma. Next, this article will analyze in detail the indications, usage, dosage, and precautions of ixazomib.

1. Indications

Ixazomib is mainly used to treat multiple myeloma (Multiple Myeloma, MM), a cancer caused by abnormal proliferation of plasma cells in the bone marrow. It is particularly suitable for patients who have received at least one prior therapy. Patients with multiple myeloma often face the challenge of recurring disease. Through its unique mechanism, ixazomib can effectively inhibit the proliferation of cancer cells and delay the progression of the disease. Typically, ixazomib is used in combination with lenalidomide and dexamethasone, and this triple-drug combination has shown greater efficacy than monotherapy.

As a proteasome inhibitor, ixazomib selectively inhibits the function of the proteasome and changes the protein metabolism pathways in cancer cells, prompting tumor cells to accumulate excessive damaged proteins, thereby triggering cell death. Compared with traditional chemotherapy drugs, ixazomib is highly selective for tumor cells and causes relatively little damage to normal cells, making it a relatively safe and effective targeted therapy drug.

2. Usage and dosage

The recommended dose of ixazomib is4 mg taken orally once weekly. The specific medication plan is: patients take the medication on days 1, 8, and 15, and each cycle is 28 days. This usage follows the standard cyclical treatment principle, that is, taking the drug for the first three weeks of each month and taking it off for the fourth week to reduce possible side effects of the drug and provide the body with time to recover.

To ensure efficacy and reduce side effects, ixazomib should be taken at least1 hour before a meal or 2 hours after a meal. When taking the drug, the dose should be adjusted according to the patient's physical condition, and is usually personalized based on liver function, kidney function, and individual tolerance to the drug. Patients with impaired hepatic function should use ixazomib with extreme caution and dose adjustments may be required.

3. Precautions

1. Allergic reactions: Although rare, ixazomib may cause allergic reactions, including rash, itching, difficulty breathing, etc. If these symptoms occur, the medication should be stopped immediately and seek medical attention.

2. Myelosuppression: Ixazomib may cause bone marrow suppression, which is manifested by a decrease in the number of platelets, red blood cells, or white blood cells. Patients need to undergo regular blood tests during treatment to monitor bone marrow function. If serious blood system problems occur, treatment may need to be temporarily stopped or the dose adjusted.

3. Monitoring of liver and kidney function: When patients with impaired liver and kidney function use ixazomib, special attention should be paid to its impact on these organs. Especially patients with impaired liver function may need to reduce the dose when using the drug. Regular monitoring of liver and kidney function is essential to ensure medication safety.

4. Gastrointestinal reactions: One of the common side effects of ixazomib is gastrointestinal reactions, and patients may experience nausea, vomiting, diarrhea and other symptoms. To alleviate these discomforts, patients are advised to avoid eating greasy foods before and after taking the medicine, and to report relevant symptoms to their doctor in a timely manner.

Reference materials:https://www.ninlaro.com/